147 related articles for article (PubMed ID: 22818644)
1. Tissue plasminogen activator and stroke: review of the literature for the clinician.
DeMers G; Meurer WJ; Shih R; Rosenbaum S; Vilke GM
J Emerg Med; 2012 Dec; 43(6):1149-54. PubMed ID: 22818644
[TBL] [Abstract][Full Text] [Related]
2. Intravenous Recombinant Tissue Plasminogen Activator and Ischemic Stroke: Focused Update of 2010 Clinical Practice Advisory From the American Academy of Emergency Medicine.
Meurer WJ; Barth B; Abraham M; Hoffman JR; Vilke GM; DeMers G
J Emerg Med; 2018 May; 54(5):723-730. PubMed ID: 29545057
[TBL] [Abstract][Full Text] [Related]
3. Role of tissue plasminogen activator in acute ischemic stroke.
Hatcher MA; Starr JA
Ann Pharmacother; 2011 Mar; 45(3):364-71. PubMed ID: 21386027
[TBL] [Abstract][Full Text] [Related]
4. Optimizing the management of acute ischaemic stroke: a review of the utilization of intravenous recombinant tissue plasminogen activator (tPA).
Eissa A; Krass I; Bajorek BV
J Clin Pharm Ther; 2012 Dec; 37(6):620-9. PubMed ID: 22708668
[TBL] [Abstract][Full Text] [Related]
5. [Thrombolytic therapy with tPA for the treatment of acute stroke. The Standard Treatment with Alteplase to Reverse Stroke study].
Di Pasquale G
Ital Heart J Suppl; 2000 Jul; 1(7):947-8. PubMed ID: 10935744
[No Abstract] [Full Text] [Related]
6. A review of barriers to thrombolytic therapy: implications for nursing care in the emergency department.
Johnson M; Bakas T
J Neurosci Nurs; 2010 Apr; 42(2):88-94. PubMed ID: 20422794
[TBL] [Abstract][Full Text] [Related]
7. Barriers to administering intravenous tissue plasminogen activator (tPA) for acute ischemic stroke in the emergency department: A cross-sectional survey of stroke centers.
Hargis M; Shah JN; Mazabob J; Rao CV; Suarez JI; Bershad EM
Clin Neurol Neurosurg; 2015 Aug; 135():79-84. PubMed ID: 26047090
[TBL] [Abstract][Full Text] [Related]
8. Tissue plasminogen activator thrombolytic therapy for acute ischemic stroke in 4 hospital groups in Japan.
Kono S; Deguchi K; Morimoto N; Kurata T; Deguchi S; Yamashita T; Ikeda Y; Matsuura T; Narai H; Omori N; Manabe Y; Yunoki T; Takao Y; Kawata S; Kashihara K; Abe K
J Stroke Cerebrovasc Dis; 2013 Apr; 22(3):190-6. PubMed ID: 21968092
[TBL] [Abstract][Full Text] [Related]
9. Thrombolytic therapy with alteplase for ischaemic stroke.
Drug Ther Bull; 2009 Feb; 47(2):14-8. PubMed ID: 19193701
[TBL] [Abstract][Full Text] [Related]
10. The use and misuse of thrombolytic therapy within the Veterans Health Administration.
Keyhani S; Arling G; Williams LS; Ross JS; Ordin DL; Myers J; Tyndall G; Vogel B; Bravata DM
Med Care; 2012 Jan; 50(1):66-73. PubMed ID: 22182924
[TBL] [Abstract][Full Text] [Related]
11. Scientific Rationale for the Inclusion and Exclusion Criteria for Intravenous Alteplase in Acute Ischemic Stroke: A Statement for Healthcare Professionals From the American Heart Association/American Stroke Association.
Demaerschalk BM; Kleindorfer DO; Adeoye OM; Demchuk AM; Fugate JE; Grotta JC; Khalessi AA; Levy EI; Palesch YY; Prabhakaran S; Saposnik G; Saver JL; Smith EE;
Stroke; 2016 Feb; 47(2):581-641. PubMed ID: 26696642
[TBL] [Abstract][Full Text] [Related]
12. EMS mythology. EMS myth #2. Thombolytic therapy is the standard of care for acute ischemic stroke.
Bledsoe BE
Emerg Med Serv; 2003 Apr; 32(4):63-5. PubMed ID: 12705219
[No Abstract] [Full Text] [Related]
13. Utilization of intravenous tissue plasminogen activator for ischemic stroke: are there sex differences?
Allen NB; Myers D; Watanabe E; Dostal J; Sama D; Goldstein LB; Lichtman JH
Cerebrovasc Dis; 2009; 27(3):254-8. PubMed ID: 19176959
[TBL] [Abstract][Full Text] [Related]
14. Why are eligible thrombolysis candidates left untreated?
Hills NK; Johnston SC
Am J Prev Med; 2006 Dec; 31(6 Suppl 2):S210-6. PubMed ID: 17178305
[TBL] [Abstract][Full Text] [Related]
15. The totaled health risks in vascular events (THRIVE) score predicts ischemic stroke outcomes independent of thrombolytic therapy in the NINDS tPA trial.
Kamel H; Patel N; Rao VA; Cullen SP; Faigeles BS; Smith WS; Flint AC
J Stroke Cerebrovasc Dis; 2013 Oct; 22(7):1111-6. PubMed ID: 23122722
[TBL] [Abstract][Full Text] [Related]
16. Acute stroke management in the elderly.
Zeevi N; Chhabra J; Silverman IE; Lee NS; McCullough LD
Cerebrovasc Dis; 2007; 23(4):304-8. PubMed ID: 17199089
[TBL] [Abstract][Full Text] [Related]
17. Tissue plasminogen activator for acute ischemic stroke: a New York city emergency medicine perspective.
Chan YF; Kwiatkowski TG; Rella JG; Rennie WP; Kwon RK; Silverman RA
J Emerg Med; 2005 Nov; 29(4):405-8. PubMed ID: 16243196
[TBL] [Abstract][Full Text] [Related]
18. Thrombolysis with alteplase 4.5-6 hours after acute ischemic stroke.
Zhang B; Sun XJ; Ju CH
Eur Neurol; 2011; 65(3):170-4. PubMed ID: 21372577
[TBL] [Abstract][Full Text] [Related]
19. Current status of intravenous thrombolysis for acute ischemic stroke in Asia.
Sharma VK; Ng KW; Venketasubramanian N; Saqqur M; Teoh HL; Kaul S; Srivastava PM; Sergentanis T; Suwanwela N; Nguyen TH; Lawrence Wong KS; Chan BP
Int J Stroke; 2011 Dec; 6(6):523-30. PubMed ID: 22111797
[TBL] [Abstract][Full Text] [Related]
20. Intravenous thrombolysis with neuroprotective therapy by edaravone for ischemic stroke patients older than 80 years of age.
Kono S; Deguchi K; Morimoto N; Kurata T; Yamashita T; Ikeda Y; Narai H; Manabe Y; Takao Y; Kawada S; Kashihara K; Takehisa Y; Inoue S; Kiriyama H; Abe K
J Stroke Cerebrovasc Dis; 2013 Oct; 22(7):1175-83. PubMed ID: 23507462
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
